NCT07894601 Virtual Reality Intervention to Improve Comfort in Hospitalized Hematology Patients
| NCT ID | NCT07894601 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fundación para la Investigación del Hospital Clínico de Valencia |
| Condition | Hematologic Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 145 participants |
| Start Date | 2026-10-26 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 145 participants in total. It began in 2026-10-26 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this clinical trial is to determine whether virtual reality (VR) devices can improve comfort and quality of life in hospitalized adult patients with hematological malignancies who require at least 15 consecutive days of inpatient treatment. The study will include adult patients of both sexes with 18 years or more. The main questions it aims to answer are: * Does the use of virtual reality devices improve the overall comfort of patients hospitalized with hematological malignancies? * Does virtual reality improve patients' quality of life compared to standard clinical care without the use of this technology? * What are the immediate effects of virtual reality on patient well-being, and what potential adverse effects may arise during its use? * How do patients perceive the use of virtual reality during their hospital stay? The researchers will compare two groups: * Group A: Virtual reality intervention: Participants will use virtual reality devices for 15 minutes on days 5, 8, 15, and 22 of the study. They will be able to choose from a selection of virtual natural landscapes, providing an immersive distraction during their hospitalization. * Group B: Control group: Participants will receive standard clinical care without the virtual reality intervention. Participants will be randomly assigned to one of the two groups. Comfort and quality of life will be assessed using the General Comfort Questionnaire (GCQ) and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), both of which will be administered on days 5 and 22 of the study. Additionally, the immediate effects of virtual reality will be evaluated by measuring vital signs and assessing symptoms before and after the intervention, including any potential discomfort, dizziness, or nausea related to the use of this technology. The study aims to recruit approximately 145 participants across three hospitals in Valencia, Spain. The results could help determine whether virtual reality serves as a useful non-pharmacological nursing intervention for improving comfort and well-being during a prolonged hospital stay due to hematological malignancies.
Eligibility Criteria
Inclusion Criteria: * Male and female patients, aged 18 or more and different racial backgrounds. * Diagnosed with a hematological condition. * Hospital stay of 15 days or longer to receive treatment for a diagnosed hematological malignancy. Exclusion Criteria: * Language barriers or physical and/or cognitive impairments that prevent patients from understanding the intervention or completing the study assessment tools. * History of photosensitive epilepsy and/or intolerance to virtual reality. * Failure to provide informed consent or withdrawal of informed consent.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07894601 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hematologic Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07894601 currently recruiting?
Yes, NCT07894601 is actively recruiting participants. Contact the research team at julia.carrio@uv.es for enrollment information.
Where is the NCT07894601 trial being conducted?
This trial is being conducted at Valencia, Spain, Valencia, Spain.
Who is sponsoring the NCT07894601 clinical trial?
NCT07894601 is sponsored by Fundación para la Investigación del Hospital Clínico de Valencia. The trial plans to enroll 145 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.